Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Disease caused by Neisseria meningitidis is a worldwide problem (1). Epi- demics of meningococcal disease regularly occur in the "meningitis belt" of sub-Saharan Africa and in Asia (2-5) and high or increasing levels of endemic meningococcal disease have been reported recently in the UK (6), New Zealand (7), Cuba (8), Brazil (9), Norway (10), and the Pacific Northwest of the United States (11). Meningococcal disease predominantly affects children and has a high mortality, which has remained unchanged for 30 years, despite advances in antibiotics and intensive care (12). Efforts have therefore been made to understand the pathophysiology of the disease and use this knowledge to improve treatment and develop novel therapies.

Original publication




Journal article


Methods Mol Med

Publication Date





375 - 410